| Species |
Cynomolgus |
| Protein Construction |
ANXA1 (Ala2-Asn346)
Accession # XP_005581995.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
39.69 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 39.69 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Atherosclerosis, characterized by the formation of fat-laden plaques, is a chronic inflammatory disease. ABCA1 promotes cholesterol efflux, reduces cellular cholesterol accumulation, and regulates anti-inflammatory activities in an apoA-I- or ANXA1-dependent manner. The latter activity occurs by mediating the efflux of ANXA1, which plays a critical role in anti-inflammatory effects, cholesterol transport, exosome and microparticle secretion, and apoptotic cell clearance. |
| Synonyms |
Annexin I; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; p35; ANX1; LPC1; Annexin A1; Annexin-1; ANXA1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
